Eli A. Friedman, M.D.

Within the past three years, Dr. Friedman has received grant/research support from Alteon.

Release Date: 04/02/2003
Termination Date: 04/02/2006

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

• Discuss the incidence and prevalence of end-stage renal disease in the United States including an awareness of the dominance of hypertension and diabetes as precipitating causes
• Discuss the impact of race on the incidence of kidney failure with associated presentation of the puzzle of why African American, Hispanic, and Native American ESRD patients have better survival during maintenance hemodialysis than do whites
• Define and describe the concept of renoprotection as the detection and proactive treatment of the broad based population of those destined to deteriorate into ESRD.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity